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The authors have previously shown that 40% of patients
whose ventricular arrhythmias respond to propranolol
require plasma concentrations in excess of those pro-
ducing substantial beta-receptor blockade (> 150 ng/ml).
However, the electrophysiologic actions of propranolol
have only been examined in human beings after small
intravenous doses achieving concentrations of less than
100 ng/ml. In this study, the electrophysiologic effects
of a wider concentration range of propranolol was ex-
amined in nine patients. Using a series of loading and
maintenance infusions, measurements were made at
baseline, at lowmean plasma propranolol concentrations
(104 ± 17 ng/ml) and at high concentrations (472 ± 68
ng/ml). Significant (p < 0.05) increases in AH interval
and sinus cycle length were seen at low concentrations
of propranolol, with no further prolongation at the high
concentrations; these effectsare typical of those produced
by beta-blockade, However, progressive shortening of
the endocardial monophasic action potential duration
The beta-receptor blocking agent propranolol has long been
known to suppress some ventricular arrhythmias (1-3). Re-
cent work in our laboratory (4) showed that more than 70%
of unselected patients with chron ic ventricular arrhythmias
responded to propranolol , but that a very wide plasma con-
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and QTc interval were seen over the entire concentration
range tested (p < 0.05). At high concentrations, there
was significant (p < 0.05) further shortening of both the
QTc and monophasic action potential duration beyond
that seen at low propranolol concentrations, along with
a progressive increase in the ratio of the ventricular
effective refractory period to monophasic action poten-
tial duration. No significant changes were seen in HV
interval, QRS duration or ventricular effective refrac-
tory period.
In summary, the concentration-response relations for
atrioventricular conductivity and sinus node automat-
icity were flat above concentrations of 150ng/ml. On the
other hand, the durations of the monophasic action po-
tential and the QTc interval shortened at high concen-
trations. It is concluded that propranolol, in addition to
blocking beta-receptors, produces other beta-receptor
independent electrophysiologic effects in human beings.
centration range (10 to 1,000 ng/ml) was required to produce
this effect. In addition , whereas substantial beta-receptor
blockade is evident at plasma concentrations of 25 to 150
ng/ml (5-9), 40% of our patients required concentrations
in excess of 150 ng/ml for arrhythmia suppression. We
hypothesized that the antiarrhythm ic responses seen at high
plasma concentrations might be related to electrophysiologic
actions other than beta-receptor blockade. However, the
electrophy siologic actions of propranolol in human beings
have only been examined after relatively small intravenous
doses that achieved low plasma propranolol concentrations
(5 to 29 ng/rnl) (10, II ). We now report our evaluation of
concentration-response relati ons for the electrophysiologic
actions of propranolol over the wide range of concentrations
required for the antiarrhythmic effects in our previous study.
Methods
Study patients. Ten patients with stable ventricular ar-
rhythmias (nonsustained ventricular tachycardia in five and
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Figure 1. Projected time course of plasma propranolol concen-
trations as a result of the infusion protocol. The arrows designate
the times when electroph ysiologic measurements were obtained.
Plasma propranolol was measured just before and after the re-
cord ings of electrophysiologic data.
electrode (ABO trading, Tullv. 11 38:S-430 41 Kullavik,
Sweden) using techniques developed by Olsson, Brorson
and co-workers (13,14). From the right atrium, the catheter
was advanced across the tricuspid valve and brought in
contact with the endocardium of the right ventricular sep-
tum. When a monophasic waveform appeared, suction was
applied ( - 100 mm Hg) for not more than 3 minutes. An
intracavitary electrocardiogram was obtained by using an
electrode at the tip of the suction catheter and a reference
electrode on the right leg. If this signal showed an injury
current. simultaneous monophasic action potential signals
were not included in the analysis.
Monophasic action potential duration . This interval was
determined during ventricular pacing at a constant cycle
length of 500 ms. After each recording, the suction electrode
catheter was withdrawn slightly and advanced again to con-
tact endocardium when further recordings were required.
The monophasic action potential signal and the unipolar
electrogram were amplified with a direct current-coupled
Electronics for Medicine differential amplifier(model PHD)
and recorded using an Electronics for Medicine model DR-
8 recorder with frequency response of 0 to 1,000 Hz at 100
mm/s. The duration of at least three monophasic action
potentials was measured at 90% repolarization and then
averaged. The typical monophasic action potentialrecording
shown in Figure 2 illustrates the method of measuring at
90,*, repolarization. After the measurements of monophasic
action potentialduration had become stable, recordingswere
made after 30 beats paced from the right ventricle. Mea-
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ventricularcouplets in nine) without known reversible cause
participated in this study. There were nine men and one
woman, aged 30 to 58 years (mean 52). Four had ischemic
heart disease, and two each mitral valve prolapse. cardio-
myopathy and no structural heart disease. None had unstable
angina, chronic obstructive lung disease, congestive heart
failure (New York Heart Association [NYHAj functional
class 1lI or IV), preexisting abnormalities in conduction or
unstable concurrent illness. Patients with very high fre-
quency ventricular arrhythmia were not candidates for study
because the presence of numerous ectopic beats could in-
terfere with reliable measurement of the electrophysiologic
variables.
The patients were admitted to the Clinical ResearchCen-
ter of Vanderbilt University Hospital. and all medications
were withdrawn for a period sufficient to allow their elim-
ination (at least four half-lives). The study was approved
by the Committee for the Protection of Human Subjects of
Vanderbilt University (initial approval June 9, 1976), and
all patients gave informed written consent.
Establishment of propranolol infusion rates. A stan-
dard series of loading and maintenance infusions of pro-
pranolol was administered (Fig. I) to achieve the desired
pseudo-steady state levels. Before the infusions, each pa-
tient was given a test dose of intravenous propranolol. O. I
mg/min for 10 minutes. Previous experience suggested that
this test dose would safely determine if a patient could
tolerate high dosages of intravenous propranolol. The in-
fusion rates were an initial loading dose of 1.0 mg/min for
20 minutes, a maintenance infusion of 0.1 mg/min. a second
loading dose of 3.0 mg/min for 25 minutes and a second
maintenance infusion of 0.6 mg/min. These rates were de-
signed to achieve plasma propranolol concentrations of 100
ng/ml (first maintenance infusion) and then 500 ng/ml (sec-
ond maintenance infusion). Because of the marked inter-
individual variability in propranolol pharmacokinetics. this
series of infusions was tested in each patient approximately
I week before the electrophysiologic study and modified if
necessary to achieve plasma concentrations in the desired
range.
Electrophysiologic studies. No medications were ad-
ministered for at least 72 hours before the electrophysiologic
study. Electrophysiologic measurements were recorded at
baseline and 20 minutes after the beginning of each main-
tenance infusion of propranolol. Plasma propranolol con-
centrations. serum potassium and lidocaine concentrations
(from local anesthesia) were measured before and just after
the electrophysiologic recordings.
Using sterile technique, a bipolar ventricular pacingelec-
trode, a tripolar electrode for obtaining a His bundle elec-
trogram and a suction bipolar electrode for recording mono-
phasic action potentials were inserted via through the fem-
oral veins. The ventricular monophasic action potential re-
cordings (12) were made using a bipolar endocardialsuction
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Results
Plasma propranolol concentrations attained during
the electrophysiologic studies (Fig. 3). The first mainte-
nance infusions achieved a mean concentration of 104 ±
17 nglml before the electrophysiologic measurements and
104 ± 11 nglml after these measurements. The second
maintenance infusions achieved concentrations of 518 ±
28 nglml before and 472 ± 68 nglml after the electro-
physiologic measurements. A mean total of 116 ± 12 mg
of intravenous propranolol was administered without side
effects in any of the patients. The rate of the second main-
tenance infusion was increased to 0.8 mglmin in two patients
as a result of the initial propranolol infusion before the study.
There was no difference in the extent of propranolol plasma
binding at low (15 ± 2.7% unbound) and at high (15.5 ±
3.4% unbound) concentrations. In one patient, a plasma
lidocaine level above 1 ILg/ml was recorded; this patient's
data have been excluded from analysis. There was no sig-
nificant change in serum potassium concentration during the
serial propranolol infusions.
Electrophysiologic actions of propranolol. Significant
increases in AH interval and sinus cycle length were seen
at the lower concentrations of propranolol (compared with
control) (Table I). No further prolongation in these intervals
was observed at the higher concentrations of propranolol.
The QTc interval and the monophasic action potential
duration were significantly shortened at low concentrations
Figure 2. Typical monophasic action potential which illustrates
the method used to measure 90% repolarization. mAPD = mono-
phasic action potential duration.
surements were made by two observers and agreed to by
consensus.
Right ventricular effective refractory period. This period
was measured by the extrastimulus technique with the elec-
trode catheter in constant position at the right ventricular
apex. A Medtronic model 5352 programmable stimulator
was used to pace the right ventricle at a cycle length (SISI)
of 500 ms and introduce a premature extrastimulus (S2) (all
at twice diastolic threshold). The premature stimulus (S2)
was introduced late in diastole and the S IS2 interval pro-
gressively shortened at 2 ms intervals until ventricular re-
fractoriness was encountered. The premature stimulus was
delivered every 20 to 25 paced beats.
Electrocardiographic intervals. Surface electrocardio-
graphic leads II and VI and the His bundle electrogram were
recorded on the Electronics for Medicine DR-8 recorder.
The PR, QRS, QT and RR intervals were measured for each
recording; the rate-corrected QT interval (QTc) was cal-
culated from the formula: QTc = QTI VRR.
Propranolol assay. Blood samples were drawn into
heparinized glass tubes with ground glass stoppers and ali-
quots of plasma were separated. The plasma was stored at
- 15° until assayed for propranolol using a high perfor-
mance liquid chromatographic procedure (16). The extent
of protein binding was determined by equilibrium dialysis
using 3H-propranolol (16,17).
Statistical analysis. Analysis of variance was used to
assess the significance of changes from control observed
during the two maintenance propranolol infusions. The Neu-
man-Keuls test was used to assess the significance of mul-
tiple comparisons. A probability (p) less than 0.05 was
sufficient to reject the null hypothesis. Data are presented
as mean ± standard error.
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of propranolol. However, at high concentrations of pro-
pranolol there was further small but significant shortening
(p < 0.05) in both the QTc interval and monophasic action
potential duration (Fig . 4). A superimposition of mono-
phasic action potentials of one patient at baseline and at low
and high concentrations of propranolol is shown in Figure
5. The ventricular effective refractory period was unchanged
at both low and high concentrations of propranolol. There
was a significant increase in the ratio of the ventricular
effective refractory period to monophasic action potential
duration at low concentrations of propranolol and a further
increase (p < 0.05) in this ratio at high concentrations of
propranolol. Figure 6 contrasts the increases in this ratio
that occurred over the whole range of propranolol concen-
trations to the increase in AH interval that occurred at low
concentrations. No significant changes from control were
observed in the HV interval or QRS duration at either low
or high concentrations of propranolol.
Because these patients had a low frequency of ventricular
arrhythmias while ambulatory and the infusions were per-
formed for relatively short durations (less than 4 hours)
under conditions of supine bed rest, assessment of the an-
tiarrhythmic efficacy of intravenous propranolol was not
attempted.
Discussion
Plasma propranolol concentrations of 40 to 150 nglml in
human beings are sufficient to produce substantial beta-
receptor blockade (5-9), whose major electrophysiologic
action is prolongation of the AH interval and sinus slowing
(lO,Il,18). Our data show that at high plasma concentra-
tions of propranolol, electrophysiologic effects apart from
those associated with beta-receptor blockade can be de-
Table 1. Electrophysiologic Actions of Low and High
Concentrations of Propranolol in Nine Patients
Baseline Maintenance 1 Mamtenance II
Plasma propranolol 0 104 ::: 17 472 ::: 68
(nglm\)
Sinus RR interval§ 826 ::: 19 947 ::: 31' 991 ::: 29
AH interval§ 109 ± 18 125 ± 20t 124 ::: 20
HV interval§ 47 ± 13 48 ::: 14 49 ± IS
VERP§ 222 ::: 17 229 ± 13 228 ± IS
mAPD§ 272 ::: 31 267 ::: 33' 225 ::: 22:1:
QTc interval§ 418 ::: 31 390 ::: 44' 380 ::: 45:1:
VERP/mAPD ratio 0.80 ± 0.07 0.86 ± 0.07* 0.90 ± 0.06:1:
*p < 0.05. t P < 0.01 = maintenance I compared WIth basehne :l:p
< 0.05 = maintenance II compared with maintenance I.
§Electrophysiologic data in milhseconds .
mAPD = monophasic action potential duration; VERP = ventricular
effective refractory period.
tected . These additional effects, a decrease in monophasic
action potential duration and QTc interval and an increase
in the ratio of ventricular effective refractory period to
monophasic action potential duration, occurred over the range
of concentrations required by some patients for suppression
of ventricular arrhythmias (4).
Previous studies on electrophysiologic properties of
propranolol. Few studies systematically examined the ef-
fects of propranolol on repolarization (QTc and monophasic
action potential recordings). In agreement with our results ,
Seides et al. (11) and Stem and Eisenberg (19) found sig-
nificant QTc shortening with propranolol. However, Echt
et al. (20) showed only nonsignificant shortening of QT and
monophasic action potential duration with intravenous pro-
pranolol. The explanation for this discrepancy may relate
to the manner in which propranolol was administered in
their study. In that study, propranolol was infused over 15
minutes and electrophysiologic recordings were started only
after discontinuing the infusion . Therefore, these measure-
ments were taken at a time when plasma concentrations
would be falling rapidly (distribution phase), a factor that
may explain the lack of significant changes. Furthermore,
Pruett et al. (21) showed that high concentrations (500 ng/ml)
of d.l-propranolol in vitro also produced action potential
duration shortening. They also found this effect with d-
propranolol, a much weaker beta-receptor blocking agent
than the levo isomer (22). Similarly, Harrison et al. (23)
reported that 6-hydroxydopamine pretreatment did not alter
propranolol-induced shortening of action potential duration,
again suggesting this to be a nonbeta-mediated effect. Al-
though local anesthetic properties have been ascribed to
propranolol in vitro, these require much higher concentra-
tions than those achieved clinically (24,25). Furthermore,
when propranolol shortened action potential duration in vitro
(21) , it had no effect on phase 0 upstroke, suggesting that
action potential duration shortening was not a reflection of
this local anesthetic property . The mechanism of the action
potential duration shortening produced by propranolol there-
fore remains uncertain .
Data from animal studies also suggest that high concen-
trations of propranolol may alter the electrophysiologic
properties of ventricular tissue . Jaillon et al. (26) reported
no change in ventricular refractorines s after intravenous pro-
pranolol (1.2 mg/kg). However , Brorson et al. (27) and
Dawson et al. (28) reported that propranolol (500 to I ,000
ng/rnl) prolonged refractoriness, action potential duration
and AH interval in anesthetized dogs. The latter two changes
were reversible by isoproterenol although the alteration in
refractoriness was not, again raising the possibility that high
concentrations of propranolol exerted nonbeta-mediated ef-
fects. These results are at variance with those we found in
patients; the explanation probably lies in the use of general
anesthesia in the dog studies . General anesthesia can sub-
stantially increase ventricular refractoriness (29,30) and al-
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Figure 4. The relationbetween plasmapropranolol and durations
of monophasic actionpotential (mAPD) (A) and QTc interval (B).
ter action potential duration by changing sympathetic tone
(31,32). In vitro work suggests that the dependence of the
action potential duration on catecholamines may be a result
of the interplay between alpha- and beta-receptor effects:
propranolol usually shortens action potential duration but in
the presence of excess catecholamines propranolol is re-
ported to prolong action potential duration (33).
Figure 5. Superimposition of monophasic actionpotentials of one
patient at baseline, low and high concentrations of propranolol.
M) and M2 = maintenance infusions I and II, respectively.
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Relation to antiarrhythmic efficacy of propranolol.
This study was not designed to assess whether the progres-
sive shortening of action potential duration is responsible
for the antiarrhythmic efficacy seen in some patients at these
high concentrations. Theoretically, shortening of action po-
tential duration in the absence of a change in ventricular
refractoriness could have antiarrhythmic effects, because the
conduction velocity of a premature beat may be influenced
by the degree to which surrounding tissue has repolarized
(34,35). Acceleration of repolarization by propranolol may
minimize the decremental conduction of a premature ven-
tricular beat and so alter the conditions predisposing to reen-
try. The phenomenon of preventing local and graded re-
sponses by propranolol has already been demonstrated in
Purkinje fibers by David and Tempte (25).
Another theoretical mechanism for antiarrhythmic effi-
cacy at high concentrations in some patients may relate to
the progressive increase in the ventricular effective refrac-
tory period/monophasic action potential duration (ERPI
mAPD) ratio seen at these concentrations. A change in the
ERP/mAPD ratio generally reflects a change in membrane
responsiveness and raises the possibility of a sodium channel
effect. Although it is plausible that these electropharma-
cologie changes may be responsible for antiarrhythmic ef-
ficacy, we have no direct data to support a cause-effect
relation.
In this study, the pharmacologic actions of propranolol
were assessed after its short-term administration; these ac-
tions may not be identical to those seen during prolonged
oral therapy with propranolol. Raine and Vaughan Williams
(36) showed that during long-term treatment of rabbits with
propranolol, alterations in sympathetic nervous system tone
may occur and so alter the effect of propranolol on repo-
larization. In keeping with these data, Edvardsson and Ols-
son (37) reported that although acute metroprolol treatment
lACC Vol. 2. No 6
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Figure6. Relation between plasma propranolol concentration and
changes in ratio of ventricular effective refractory period to mon-
ophasic action potential duration (vERP/mAPD) (left panel) and
changes in AH interval (right panel).
did not affect repolarization. chronic treatment was asso-
ciated with prolongation of monophasic action potential du-
ration and ventricular refractoriness.
In summary, in our study, propranolol exerted two types
of effect. The first. seen at low concentrations. was typical
of beta-blockade (AH prolongation and sinus slowing).
However. at higher concentrations, action potential duration
shortening became evident. while no increment in beta-
blocking action was noted. Propranolol, therefore. exerts
electrophysiologic effects in human beings by two mecha-
nisms. one related to beta-blockade and the other indepen-
dent of beta-blockade.
References
I. Gianelly R, Griffin JR, Harrison DC. Propranolol in the treatment and
prevention of cardiac arrhythmias Ann Intern Med 1967;66:667-74.
2. Gibson D. Sowton E The use of beta adrenergic receptor blocking
drugs on dysrhythmias . Prog Cardiovasc Dis 1969;12:16-50.
3. Winkle RA, Popes MG. Goodman DJ. Fitzgerald JW. Schroeder JS.
Harrison DC. Propranolol for patients with mitral valve prolapse Am
Heart J 1977;93.422-8.
4 Woosley RL. Kornhauser DK. Smith RL. et al Suppression of chronic
ventricular arrhythmias With propranolol. Circulation 1979;60:819- 27
5. Collart DJ. Shand DG Plasma propranolol levels In the quanuauve
assessment of ,a-adrenergic blockade in man. Br Med J 1970.3:731- 11
6. Zacest R. Koch-Weser 1. Relation of propranolol level to ,a-blockade
during oral therapy. Pharmacology 1972:7:178-82
7. Pine M. Favrot L. Smith S. McDonald K. Chidsey CA. Correlation
of plasma propranolol concentration with therapeutic response in pa-
tients with angina pectori s. Circulation 1975;52:886-93.
8. Chidsey C. Pine M. Favrot L. et al. The use of drug concentration
measurements in studies of the therapeutic response to propranolol.
Postgrad Med J 1976;52:26-32.
9 Serhn ML Orme LE. Baber NS. Sibeon RG. Law E. Breckenridge
A. Propranolol in the control of blood pressure . A dose-response study.
Chn Pharmacol Ther 1980;27:586-92
10 Berkowitz WD , Wit AL, Lau SH. Steiner C, Damato AN. The effects
of propranolol on cardiac conduction . Circulation 1969:40:855-65 .
II. Seides SF . Josephson M. Batsford WP. Wersfogel GM, Lau SH.
Damato AN . The electrophysiology of propranolol In man. Am Heart
J 1974;88:733-40.
12. Hoffman BF. Cranefield PF. Lepeschkin E. Surawicz B. Herrlich H.
Comparison of cardiac monophasic action potentials recorded by in-
tracellular and suction electrodes . Am J Physiol 1959;196:1297-304.
13. Olsson B. Varnauskas E. Korsgren M. Further Improved method for
measuring action potentials of the intact heart . J Electrocardiol
1971;4:19-23 .
14. Brorson L. Olsson B. Right atnal monophasic action potentials In
healthy males . Studies during spontaneous sinus rhythm and atnal
pacing. Acta Med Scand 1976;199:433-40
15. Samuelsson RG. Harrison DC. Electroph ysiologic evaluation of en-
carrude With the use of monophasic action potent ial recording s Am
J Cardiel 1981;48:871-5 .
16. Wood AJJ. Carr K, Vestal RE, Belcher S. Wilkinson GR. Shand DG
Direct measurement of propranolol broavailability during accumula-
tion to steady state. Br J Chn Pharmacol 1978;6:345-50.
17. Kornhauser DM. Wood AJL Vestal RE. Wilkmson GR , Branch RA.
Shand DG. Biological determinants of propranolol disposition in man.
Chn Pharmacol Ther 1978;23:165-74.
18. Wit AL. Hoffman BF. Rosen MR. Electrophysiology and pharma-
cology of cardiac arrhythrmas . IX. Cardiac electrophysiologic effects
of beta adrenergic receptor stimulanon and blockade Part A Am
Heart J 1975;90:521-33 .
19 Stem S. Eisenberg S. The effect of propranolol on the electrocardio-
gram of normal subjects. Am Heart J 1969:77:192.
20. Echt OS. Berte LE. Clusm WT. Samuels son RG. Harrison DC. Mason
1140 DUFF ET AL.
PROPRANOLOL ELECTROPHYSIOLOGY
JACC Vol. 2. No, 6
December 1983:1134-40
IW. Prolongation of the human cardiac monophasic action potential
by sotalol. Am I Cardiol 1982;50:1082-6.
21. Pruett IK, Walle T, Walle UK. Propranolol effects on repolarization
time in isolated Purkinje fibers: threshold tissue contents and influence
of exposure time. I Pharmacol Exp Ther 1980;21:539-43.
22. Barrett AM, Cullum VA. The biological properties of the optical
isomers of propranolol and their effects on cardiac arrhythmias. Br I
Pharmacol 1968;34:43-55.
23. Harrison LA, Wittig I, Wallace AG. Adrenergic influence on the distal
Purkinje system of the canine heart. Circ Res 1973;32:329-38.
24. Vaughan-Williams EM. Mode of action of beta-receptor antagonists
on cardiac muscle. Am I Cardiol 1966;18:399-405.
25. David LD. Tempte IV. Effects of propranolol on the transmembrane
potentials of ventricular muscle and Purkinje fibers of the dog. Circ
Res 1968;22:661-77.
26. Jaillon P, Heckle I, Weissenburger I, Cheymol G. Cardiac electro-
physiologic properties of dl-propranolol, d-propranolol, l-propranolol,
and dl-pindolol in anesthetized dogs. I Pharmacol Exp Ther
1980;212:347-57.
27. Brorson L, Reele S, Dupont W, Woosley RL, Shand D, Smith RF.
Effects of concentration and steric configuration of propranolol on AV
conduction and ventricular repolarization in the dog. I Cardiovasc
Pharmacol 1981;3:692-9.
28. Dawson AK, Reele sa, Woosley RL, Smith RF. Disparate electro-
physiologic effects of ,B-agonist in the presence of high plasma pro-
pranolol (abstr). Clin Res 1979;27:76A.
29. Laforet EG, Angelakos ET, Hegnauer AH. Ventricular excitability in
the unanesthetized dog and its modification by pentobarbital anes-
thesia. I Physiol 1957;189:596-610.
30. Smith SL, Webb WR, Fabian LW, Hagaman VD. Cardiac excitability
in ether, cyclopropane and halothane anesthesia. Anesthesiology
1962;23:766-77.
31. Roizen MF, Moss I, Henry DP, Kopin 11. Effects of halothane on
plasma catacholamines. Anesthesiology 1974;41:432-40.
32. Nikki P, Takki S, Tammisto T, Jaattela A. Effects of operative stress
on plasma catecholamines. Ann Clin Res 1972;4:146-55.
33. Ledda GF. Mannaioni PF. Effects of noradrenaline and isoprenaline
in combination with a and ,B receptor blocking substances, on the
action potentialof the cardiac Purkinje fiber. I Physiol 1973;229:99-110.
34. Weidmann S. Effects of calcium ions and local anesthetics on electrical
properties of Purkinje fibers. I Physiol (Lond) 1955;129:568-82.
35. Bassett AL, Hoffman BF. Antiarrhythmic drugs. Electrophysiologic
action. Ann Rev PharrnacoI1970;11:143-70.
36. Raine AEG, Vaughan Williams EM. Adaptation to prolonged ,B-block-
ade or rabbit atrial, Purkinje, and ventricular potentials and papillary
muscle contractions. Circ Res 1981;48:804-12.
37. Edvardsson N, Olsson SB. Effects of acute and chronic beta receptor
blockade on ventricular repolarization in man. Br Heart J
1981;45:628-36.
